Abstracts 30, 2008 within a large nationwide network of outpatient oncology clinics were studied using US Oncology's iKnowMed EMR. Costs included only those incurred within the network of outpatient oncology clinics and were derived using Medicare reimbursement rates. Patients were matched across regimens on key confounding factors at initiation of treatment: age, stage at diagnosis, ECOG performance status, and comorbidity index. A variable N:M matching ratio was used. Patients were followed through June 30, 2009. A 95% confidence intervals were estimated by bootstrapping (2500 samples) the within-cell differences in cost and time to progression (TTP) of matched patients. RESULTS: A total of 1194 patients were identified: 48 received P/P, 279 received C/P + B, and 867 received C/P. We found that P/P exhibited dominance vs. C/P + B, with higher effectiveness (mean difference in TTP = 1.7 months; CI = 1.1-2.3 months) and lower cost (mean cost difference = −$22,890; CI = $−25,445-$−20,335). Compared to C/P, P/P had higher effectiveness (mean difference in TTP = 2.0 months; CI = 1.7-2.4 months) but also higher costs (mean cost difference = $12,603; CI = $11,579-$13,667) with an incremental cost effectiveness of $6,335/progression-free month (CI = 5,404). CONCLUSIONS: This study suggests that P/P may be a cost-effective 1 st line NSCLC treatment in the outpatient community setting. Costs differences were substantial by regimen while differences in TTP were relatively small from a clinical perspective. While this preliminary study utilized conservative analytic methods and controlled for several key confounding factors, future large studies should attempt to further address selection bias and residual confounding. were identified in the SEERMedicare database using ICD-O codes for primary site and histology with a "distant" tumor in the SEER staging variable. Individuals 65 years or older at the time of diagnosis, with at least 12 months of data preceding initial diagnosis were included. The index date was defined as the date of diagnosis; subjects were followed from 30 days prior to the index date until death or the end of Medicare claims data (December 31, 2007), whichever occurred first. Chemotherapy use was identified using HCPCS codes. Resource use and health care costs were estimated using the person-years approach to account for patients having different lengths of follow-up. RESULTS: A total of 1420 subjects with mSCCHN were included in this analysis. Mean age was 74 (SD 6.7) years and 70% were males. Mean Charlson comorbidity score without malignancy was 1.4 (SD 1.6) and mean duration of follow-up was 30 months (SD 33). Forty-eight percent of patients received chemotherapy. Carboplatin (18%) was the most commonly used agent followed by paclitaxel (13%) and cisplatin (11%). The mean number of visits per patient per year was 9.7 (SD 10.7) for outpatient care and 2.9 (SD 3.7) for inpatient care. Average annual inpatient days per patient were 31.4 days (SD 51.1). About 40% of the patients received hospice care. Mean total annual health care costs per patient were $155,307, cost of outpatient care constituted 51% and inpatient care 34%. CONCLUSIONS: Inpatient and outpatient costs are the key drivers of total health care costs for patients with mSCCHN.
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i3 Innovus, San Francisco, CA, USA, 2 i3 Innovus, Eden Prairie, MN, USA, 3 i3 Innovus, Medford, MA, USA, 4 Amgen, Inc, Thousand Oaks, CA, USA OBJECTIVES: To estimate health care utilization and costs for patients with incident metastatic squamous cell carcinoma of head and neck (mSCCHN). METHODS: Incident mSCCHN patients between 1993 and 2005 were identified in the SEERMedicare database using ICD-O codes for primary site and histology with a "distant" tumor in the SEER staging variable. Individuals 65 years or older at the time of diagnosis, with at least 12 months of data preceding initial diagnosis were included. The index date was defined as the date of diagnosis; subjects were followed from 30 days prior to the index date until death or the end of Medicare claims data (December 31, 2007) , whichever occurred first. Chemotherapy use was identified using HCPCS codes. Resource use and health care costs were estimated using the person-years approach to account for patients having different lengths of follow-up. RESULTS: A total of 1420 subjects with mSCCHN were included in this analysis. Mean age was 74 (SD 6.7) years and 70% were males. Mean Charlson comorbidity score without malignancy was 1.4 (SD 1.6) and mean duration of follow-up was 30 months (SD 33). Forty-eight percent of patients received chemotherapy. Carboplatin (18%) was the most commonly used agent followed by paclitaxel (13%) and cisplatin (11%). The mean number of visits per patient per year was 9.7 (SD 10.7) for outpatient care and 2.9 (SD 3.7) for inpatient care. Average annual inpatient days per patient were 31.4 days (SD 51.1). About 40% of the patients received hospice care. Mean total annual health care costs per patient were $155,307, cost of outpatient care constituted 51% and inpatient care 34%. CONCLUSIONS: Inpatient and outpatient costs are the key drivers of total health care costs for patients with mSCCHN.
HE3 CAN INNOVATION BE REWARDED WITH THE APPLICATION OF RIGID COST-EFFECTIVENESS THRESHOLDS? THE HER2+VE BREAST CANCER CASE STUDY
Ray J, Cirrincione A F. Hoffmann-La Roche Ltd., Basel, Switzerland OBJECTIVES: Trastuzumab (Tras) in combination with chemotherapy is the current treatment standard in patients with early and metastatic breast cancer (BC) who are HER2 positive (HER2+). Any regimen under development will have to be compared to Tras both in pivotal clinical trials and during economic assessment. This study raises important policy questions by estimating the feasibility of demonstrating cost-effectiveness (CE) against conventional UK NICE thresholds (£ 20-30,000/QALY gained) for new regimens developed in different lines of treatment for HER2+ BC and incentives for development where rigid thresholds are applied. METHODS: Three CE models were developed using rates of disease progression, survival and efficacy data from 3 Tras clinical trials: HERA for adjuvant, M77001 for 1 st -line metastatic and GBG-26 for 2 nd -line metastatic BC. Isometrics curves were generated for each model whereby each point on the curve corresponded to where the progression-free & overall survival hazard ratios and increase in total costs for the new treatment versus Tras was estimated to result in an ICER of £ 30'000/QALY. Costs and utility values were based on published literature from the UK-NHS perspective. RESULTS: Assuming a 5-year duration of efficacy in early BC (PFS hazard ratio of 0.75), the model estimated that a new treatment could be considered cost-effective with medication acquisition costs 81% above Tras. In the metastatic setting (1 st and 2 nd -line), similar incremental improvements in efficacy, for the OS and PFS hazard ratios over 5 years, suggests that a new regimen could not have medication acquisition costs more than 6-7% above Tras. CONCLUSIONS: Given current treatment costs of the background regimen, it is unlikely that any new combination regimen will be cost-effective using UK thresholds. Results were not sensitive to the magnitude of the incremental survival benefit due to the high correlation between treatment benefit, treatment duration (until cancer progression), and overall treatment costs.
HE4 CHARACTERIZATION OF FREQUENT HOSPITAL EMERGENCY DEPARTMENT (ED) USE BY UN-OR UNDERINSURED PERSONS
Khurshid A 1 , Strassels S 2 1 Integrated Care Collaboration, Austin, TX, USA, 2 University of Texas at Austin, Austin, TX, USA OBJECTIVES: ED use for non-emergencies contributes to crowding, increased health care costs, and, potentially, poor clinical outcomes. Efforts to decrease inappropriate ED use have focused on insured individuals. The purpose of this retrospective cohort study was to characterize frequent ED use among un-and underinsured individuals in central Texas. METHODS: Data were obtained from the ICare system, which includes information for > 800,000 individuals and > 5 million encounters within 24 Central Texas health care providers who arrange for or provide care for uninsured or underinsured individuals. Persons who received care from an ICare-participating organization during calendar year 2007 were included in these analyses. Frequent ED use was defined as at least 6 ED visits within either a calendar quarter or any contiguous three-month period. Linear regression was used to estimate the relation between patient characteristics and total ED visits among frequent users. RESULTS: There were 216,364 ED visits in 2007; 128,538 individuals had at least 1 ED visit and 0.7% (n = 892) were considered frequent ED users. Frequent users were mainly female (55.6%), and Caucasian (55.8%). Hispanics and African-Americans accounted for 14.2% and 17.3% of frequent users, respectively. The regression model accounted for 12.1% of variability in the outcome. Total clinic visits (beta = 0.05, p 0.037, 95% CI 0.003-0.094), inpatient admissions (beta = 1.35, p < 0.001, 95% CI 0.976-1.716) and having any mental health diagnosis in any ED visit (beta = 3.278, p < 0.001. 95% CI 2.060-4.496) were positively and statistically significantly associated with the number of ED visits among frequent users, after adjusting for age, sex, and race. CONCLUSIONS: In 2007, frequent users accounted for < 1% of ED users, and 5.4% of total ED use. A study of these frequent users may help identify opportunities for intervention to help underlying causes for these frequent visits. A comparison between drug advice, the clinical evidence through identification of trials on the CENTRAL database of the Cochrane library and a statistical analysis was performed on improvement in medical benefit (ASMR) supplied by HAS and the cost-utility estimates (CQG) of the SMC. RESULTS: The HAS and SMC had the same advice in 14/39 (36%) of the drug comparisons. The average number of trials included were 2 trials in HAS advice and 1.8 trials in SMC advice with more comprehensive detail on the efficacy in HAS advice. Each matched comparison had at least one common trial and 30% of guidance included different additional trials. The correlation between the medical improvement provided by HAS and the SMC CQG were analysed and show that for those treatments considered cost saving by the SMC the ASMR was on average 4.6. The CQG for £0-£10,000 had an average ASMR; 3.6, £10,000-£20,000; 2.8, £20,000-£30,000; 3.1, and £30,000+; 3.4, showing little correlation between ASMR and CQG. CONCLU-SIONS: The differences in guidance advice reflect the countries different HTA processes, interpretation of clinical efficacy and approaches to economics. HAS advice provided more detailed information on the clinical efficacy in comparison to SMC for these drugs. The SMC presented formal analysis of cost-effectiveness in comparison to France where economic issues are considered by the economic committee and not reported. The transparency committee implicitly uses economics as the choice of ASMR influences pricing decisions and the cost-effectiveness of treatments.
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